- Vascular Biogenics ( VBLT ) -78% after late-stage trial for ovarian cancer treatment fails ; cut to Neutral at HC Wainwright after trial failure sinks stock 79%.
- Adial Pharmaceuticals ( ADIL ) -28% as AD04 fails to best placebo in very heavy drinkers in trial .
- Revolution Medicines ( RVMD ) -15% on pricing upsized $230M equity offering .
- Bath & Body Works ( BBWI ) -10% after lowering guidance due to inflation pressures .
- Neuronetics ( STIM ) -7% .
- Baker Hughes ( BKR ) -6% after misses consensus mark in Q2; Order down 14% sequentially .
- Atara Biotherapeutics ( ATRA ) -5% .
For further details see:
Baker Hughes, Bath & Body Works, Revolution Medicines among premarket losers' pack